loading page

NEW ORAL oral formulation glucagon-like peptide 1 (GLP1) SEMAGLUTIDE
  • +1
  • Raffaele La Porta,
  • Giovanni Granata,
  • Francesco Ferrara,
  • Antonio Vitiello
Raffaele La Porta
ASUR Marche

Corresponding Author:raffaele.laporta@asurmarche.it

Author Profile
Giovanni Granata
Local Health Authority Salerno
Author Profile
Francesco Ferrara
USL 1 Umbria
Author Profile
Antonio Vitiello
Azienda Unità Sanitaria Locale Umbria 1
Author Profile


In recent years, new classes of drugs have entered the market for the treatment of type 2 diabetes mellitus (T2DM) with good efficacy on the normalization of blood glucoseandwithareductionin the risk of hypoglycaemia and with significant effects on weight reduction. One of the most promising classes in achieving these goals was that of the agonists(GLP)-1.However,adifficulty in using these drugs arisesfromsubcutaneousadministration,aroutethatisnotveryconvenientfor users and with the risk of infections. More recently, a GLP-1 agonist, semaglutide, has been developedwhichcanbeadministeredorally.Inthisreviewarticle,wediscussedtheeffectivenessof GLP-1 agonists, oral semaglutide and its therapeutic potential.